Detailed dose evidence documented for Survodutide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Not established
No approved labeled regimen
No established or recommended human dose.
Not applicable — no marketing authorization was identified in the major regulator databases reviewed as of the verification date.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
No established or recommended human dose.
Phase 2 trials used once-weekly subcutaneous administration with forced dose escalation over multiple weeks. Highest studied weekly doses: 4.8 mg (obesity Phase 2), 6.0 mg (MASH Phase 2). SYNCHRONIZE-1 studied doses adjusted up to 3.6 mg or 6.0 mg once weekly. These trial exposures are descriptive, not recommended regimens.
Not established
What is not established
No safe or effective dose has been confirmed by regulatory review. Optimal dose-escalation protocol, maximum tolerated dose, durability of effect beyond 76 weeks, and long-term safety are not established.